



Trojan Ethical Fund

All data as at 31 May 2020


www.taml.co.uk


The investment objective of the Trojan Ethical Fund is to provide capital growth (net of fees), ahead of inflation (UK Retail Price Index), over the longer term (5 to 7 years). Its investment policy is to invest across a broad range of asset classes. Whilst asset allocation will vary, in general, the investment universe will comprise high-quality, developed market equities, developed market government bonds, gold related investments, cash and money market instruments (such as treasury bills). The portfolio will be constructed with input from both top-down analysis (looking at an economy as a whole) and bottom-up analysis (study of individual securities). The Fund will invest in accordance with the parameters of its Ethical Exclusion Criteria.

Prices
114.62p
'O' accumulation shares

114.48p
'O' income shares

Fund Size





Total Return to 31 May 2020	22/03/19 Since launch		
Trojan Ethical Fund O Acc	+14.6%	+11.9%	+7.2%
UK Official Bank Base Rate	+0.8%	+0.6%	+0.2%
UK Retail Price Index	+2.7%	+1.2%	+0.5%
FTSE All-Share Index (TR)*	-10.7%	-11.2%	-16.1%
Discrete Calendar Annual Returns	2019 [#] 2020 Y		2020 YTD
Trojan Ethical Fund O Acc	+	7.1%	+7.0%
*© FTSE International Limited 2020			Caurage Linnar

"© FISE International Limited 2020 #from 22 March 2019 Past performance is not a guide to future performance

Source: Lipper

May Commentary

Your Fund returned +2.2% during the month compared to +3.4% for the FTSE All-Share Index (TR).

Stock markets have cheered as Western governments began to ease lockdowns and the rate of new coronavirus cases in several countries slowed. We remain sceptical that the path to normalcy is as clear as the rally in share prices would suggest.

For those companies we own, earnings releases in the month have provided us with some insights into how they are faring. We deliberately favour well-capitalised companies with broad end-market exposures, enabling them to endure and survive bouts of hardship. Two such examples are Medtronic, held since launch, and Agilent which we added to the portfolio over the past year, both performing positively.

Medtronic is the world's largest medical device manufacturer, with products to treat a wide range of illnesses from cardiovascular disease to diabetes. With COVID-19 leading to the deferral of many elective surgical procedures, Medtronic saw its sales decline -25% in the quarter. The majority of these sales are likely to return, as they cannot be deferred indefinitely without major risk to patients' health. Thanks to


the strength of its balance sheet, Medtronic is able to continue investing behind its people and products, including remote-monitoring technology, an increasingly prized capability in the current environment.

Agilent meanwhile saw flat sales growth in the quarter, with demand for its testing equipment growing in health-related sectors, offsetting weakness in academic and energy-related sales. Geographic diversity also aided the resilience with its China business returning to growth. The company's financial strength enables it to continue investing behind its best opportunities.

Trojan Ethical Fund

All data as at 31 May 2020

www.taml.co.uk



Source: Lipper

Risk analysis since launch (22/03/19)	Trojan Ethical Fund O Acc	FTSE All-Share Index (TR)
Total Return	+14.6%	-10.7%
Max Drawdown ¹	-8.9%	-35.3%
Best Month	+4.6%	+4.9%
Worst Month	-2.0%	-15.1%
Positive Months	+71.4%	+57.1%
Annualised Volatility ²	+6.1%	+19.7%

Source: Lipper 1. Measures the worst investment period ² Measured by standard deviation of annual returns

Top 10 holdings (excluding government bonds)	% Fund
ETFS Physical Gold	7.1
Microsoft	5.2
Alphabet	4.9
Visa	4.7
Nestlé	4.5
Medtronic	4.4
ETC Physical Gold	4.4
Unilever	4.4
Colgate-Palmolive	3.2
Berkshire Hathaway	2.3
Total Top 10	45.2
17 other holdings	39.4
UK T-Bills	10.3
Cash	5.1
Total	100.0

Source: Factset, holdings subject to change

Fund information

A copy of the latest Prospectus and the KIID for each class (in English) upon which you should base your investment decision is available from Link Fund Solutions Ltd, the Fund's Authorised Corporate Director at www.linkfundsolutions.co.uk.

Structure

Sub-fund of Trojan Investment Funds UCITS

Investment Manager

Troy Asset Management Limited 33 Davies Street

London W1K 4BP Tel: 020 7499 4030 Fax: 020 7491 2445 email: busdev@taml.co.uk

Fund Manager Charlotte Yonge

Currency £ Sterling

Launch Date 22 March 2019

Ongoing Charges (capped)

'O' (ordinary) shares: 1.02% 'S' (charity) shares: 0.77%

Dividend Ex Dates

1 August (interim), 1 February (final)

Dividend Pay Dates

30 September (interim), 31 March (final)

Authorised Corporate Director

Link Fund Solutions Limited

ISIN

GB00BJP0XY24 (O Inc), GB00BJP0XX17 (O Acc) GB00BJP0Y054 (S Inc), GB00BJP0XZ31 (S Acc)

Benchmarks

For more information on the benchmarks used please refer to the 'use of benchmarks' section in the fund information sheet, available from our website

Dealing

Daily at noon Tel: 0345 608 0950

Registrar

Link Fund Administrators Limited

Auditor

Ernst & Young LLP

Depositary

The Bank of New York Mellon (International) Limited

SEDOL (O shares)

BJP0XY2 (O Inc), BJP0XX1 (O Acc) BJP0Y05 (S Inc), BJP0XZ3 (S Acc)

Pricing

"O" share class prices published daily in the FT

Important Information

Fund performance data provided is calculated net of fees unless stated otherwise. Past performance is not a guide to future performance. Overseas investments may be affected by movements in currency exchange rates. The value of an investment and any income from it may fall as well as rise and investors may get back less than they invested. The historic yield reflects distributions declared over the past twelve months as a percentage of the fund's price, as at the date shown. It does not included any preliminary charge and investors may be subject to tax on their distributions. They jield is not guaranteed and will fluctuate. The fund may use currency forward derivatives for the purpose of efficient portfolio management. Neither the views nor the information contained within this document constitute investment advice or an offer to invest or to provide discretionary investment and the latest report and accounts. The investment policy and process of the fund(s) may not be suitable for all investors. If you are in any doubt about whether the fund(s) is/are suitable for you, please contact a professional adviser. References to specific securities are included for the purposes of illustration only and should not be construed as a recommendation to buy or sell these securities. Although Troy Asset Management Limited considers the information included in this document to be reliable, no warranty is given as to its accuracy or confleteness. The opinions expressed are expressed at the date of this document and, whilst the opinions is stread are propinions expressed are expressed at the date of this document and, whilst the opinions is stread are propinions expressed at each of this document and, whilst the opinions is stread are one or more local authorities, a third country, or a public international box or or more EEA states belong. The Investors in the fund is provided without warranty or liability and may belong to a third party. In line with the Fund's prospectus, the Fund is authorised to investor information only